Sun Pharma secures ex-US, China rights to cholesterol drug lerodalcibep
Sun Pharmaceutical Industries has licensed rights from LIB Therapeutics to develop, manufacture, secure approvals for and commercialise monthly PCSK9 inhibitor lerodalcibep outside the US and China, expanding its specialty-medicines pipeline in a large cholesterol-treatment market.
The development
Sun Pharmaceutical Industries secured rights to commercialise lerodalcibep in a $3.7 billion PCSK9 market outside the US and China. The deal with LIB Therapeutics covers manufacturing, regulatory approvals and sales of the monthly cholesterol injection in licensed territories.
The numbers
- September 21
- $3.7 billion
- 12 months ended Q2 2026
- 38%
- two years
Why it matters to operators and investors
Sun Pharma adds a high-value monthly cholesterol therapy candidate to its specialty portfolio, creating a future launch opportunity across ex-US, ex-China markets pending approvals.
What to watch next
- Timing and results of regulatory submissions, approvals or requests for additional data outside the US and China.
- New cardiovascular-outcomes, durability, safety or comparative data for lerodalcibep.
- Reimbursement decisions and formulary placement in large European, Japanese, Canadian, Australian and emerging-market systems.
- Pricing and access actions by rival PCSK9 inhibitors, inclisiran and other LDL-C therapies.
- Sun Pharma disclosures on upfront payment, milestones, launch countries, capex, sales-force investment or revenue guidance.
The counter-case
The deal adds optionality rather than near-term revenue: lerodalcibep still requires regulatory approvals, and success will depend on clinical differentiation, pricing, reimbursement and Sun Pharma's ability to compete against entrenched PCSK9 therapies. Excluding the US and China removes two of the largest potential markets, while monthly dosing alone may not overcome payer preference for established brands, generics or lower-cost lipid treatments.